Camzyos (mavacamten)

pCPA File Number: 22344

Negotiation Status:

Concluded with an LOI

Indication(s):

Symptomatic obstructive hypertrophic cardiomyopathy (oHCM) of New York Heart Association (NYHA) Class II-III in adult patients.

Sponsor/Manufacturer:

Bristol Myers Squibb Canada Inc.

CDA-AMC Project Number:

SR0755-000

pCPA Engagement Letter Issued:

2024-01-15

Negotiation Process Concluded:

2024-06-20